Under the agreement, Medunik Canada will distribute Orphan’s four therapies for certain medical conditions including acute hepatic porphyria, hyperammonaema due to N-acetylglutamate synthase (NAGS) deficiency or one of three organic acidurias (isovaleric, methylmalonic or propionic), patent ductus arteriosus as well as vitamin E deficiency in chronic cholestasis.
Medunik executive vice-president Eric Gervais said, "This new strategic collaboration complements our existing alliances and represents an important milestone in our endeavor to help patients with a rare disease in Canada to benefit from the best treatments available".
Orphan Europe Recordati Group general manager and special care and orphan drugs vice-president Marco Liguori said, "We are particularly happy to work with a company like Medunik Canada which is committed to building awareness and promoting better diagnosis and care of rare disease patients in Canada."